How Retatrutide Affects ALT Liver Enzyme

ALT (alanine aminotransferase) is the most liver-specific transaminase and rises when hepatocytes are damaged or under metabolic stress. Retatrutide affects ALT through opposing short-term and long-term mechanisms:

Long-term ALT reduction (the dominant effect):

1. Hepatic steatosis clearance: The Phase 2a MASLD trial (Sanyal 2024) showed about 82 percent relative liver fat reduction at 8mg and 12mg, with about 90 percent of subjects achieving complete steatosis resolution. A non-fatty liver produces less ALT leakage.
2. Reduced de novo lipogenesis: GLP-1 receptor activation in hepatocytes reduces the synthesis of new fatty acids from carbohydrates.
3. Improved insulin sensitivity: Lower hyperinsulinaemia reduces the metabolic drive for fatty acid synthesis and lipotoxicity.
4. Anti-inflammatory effects: GLP-1 agonism reduces hepatic inflammation associated with steatohepatitis.
5. Glucagon-driven fatty acid oxidation: Unique to retatrutide, the third agonism enhances hepatic fatty acid oxidation, accelerating fat clearance beyond what GLP-1 alone achieves.

Short-term ALT elevation (transient, in first 4 to 12 weeks):

1. Rapid fat mobilisation: Dramatic weight loss in the first 2 to 3 months can transiently flood the liver with mobilised free fatty acids, producing a temporary ALT bump.
2. Caloric restriction stress: Aggressive caloric deficit alone can elevate ALT through hepatic adaptation.
3. Gallstone formation: Rapid weight loss increases gallstone risk, which can cause cholestatic ALT elevations.

Net effect over 24+ weeks is strongly favourable. Short-term, expect potential transient elevations in the first 8 to 12 weeks before the trajectory turns clearly downward.

Subjects with baseline fatty liver (MASLD/NAFLD):

• Long-term ALT reduction of 30 to 50 percent at 12mg over 24 to 48 weeks
• Liver fat reduction of about 82 percent at 8mg or 12mg (Sanyal 2024)
• About 90 percent achieve complete steatosis resolution
• ALT often normalises completely from baseline elevations of 50 to 100 U/L down to 20 to 30 U/L

Subjects with normal baseline ALT:

• Modest reduction of 5 to 15 percent over 24 to 48 weeks
• Most users see ALT in the 15 to 25 U/L range during sustained use

Short-term, first 4 to 12 weeks (any user):

• Transient ALT bump of 10 to 30 percent above baseline is possible
• Usually peaks at week 8 to 12, then declines
• Magnitude correlates with rate of weight loss; faster weight loss produces larger bumps

In bodybuilders using oral steroids:

• Retatrutide cannot prevent the acute hepatotoxicity of C17-aa oral compounds (dianabol, anadrol, anavar, superdrol, winstrol)
• It does reduce hepatic steatosis between oral cycles, lowering baseline ALT before the next cycle
• Combining retatrutide with active oral steroid use can confuse interpretation: a rising ALT during this period is most likely from the oral, not retatrutide

Timeline: Possible transient bump weeks 4 to 12. Clear downward trajectory by week 16 to 24. Maximum improvement at week 48 or later as hepatic fat clearance completes.

Baseline: ALT, AST, GGT, total bilirubin, and (if accessible) hepatic ultrasound or FibroScan. The MASLD literature suggests baseline imaging changes the interpretation significantly.

Week 4 panel: ALT, AST as part of early tolerability check. A transient bump is expected and not alarming unless severe.

Week 12 panel: Repeat ALT, AST. If still elevated above 3x upper limit at week 12, investigate (alcohol, viral hepatitis, oral steroid co-use, gallstones).

Week 24 panel: Full liver panel. By this point ALT should be trending clearly downward in subjects with baseline steatosis.

Triggers for action:

• ALT above 3x upper limit at any point: pause dose escalation, repeat in 4 weeks, investigate other causes
• ALT above 5x upper limit: hold retatrutide, evaluate for alternative cause, hepatology referral if persistent
• ALT above 10x upper limit with symptoms (jaundice, dark urine, right upper quadrant pain): urgent medical evaluation, stop retatrutide

Special situation, oral steroid co-use: Confounded interpretation. Hold oral steroids and recheck ALT after 4 weeks to isolate retatrutide's contribution.

For users with baseline fatty liver:

• Pair retatrutide with low-refined-carbohydrate, low-alcohol diet to maximise hepatic fat clearance
• Adding resistance training improves hepatic insulin sensitivity beyond what weight loss alone delivers
• Consider TUDCA 500mg twice daily during first 12 weeks if rapid weight loss is expected, to reduce gallstone risk

For users with normal baseline ALT seeing a transient bump:

• Continue dose if rise is mild (under 2x upper limit) and asymptomatic; recheck in 4 weeks
• Avoid alcohol and other hepatotoxins during this phase
• Most transient bumps resolve by week 16 to 20 as weight loss rate slows

For bodybuilders running orals concurrently:

• Hold oral steroids during retatrutide titration if possible to avoid confounded ALT interpretation
• If orals are non-negotiable, document the pattern: ALT trajectory on retatrutide alone (baseline before oral start), then add oral and watch the differential
• The acute toxicity of orals is independent of retatrutide's hepatic effects

For users with gallbladder symptoms during rapid weight loss:

• Right upper quadrant pain, especially after fatty meals, warrants gallstone evaluation
• UDCA prophylaxis (300mg daily) is reasonable if losing more than 1.5 kg/week
• Consider slowing the titration to reduce weight loss rate if symptomatic

Discontinuation: ALT remains improved for as long as weight loss is maintained. If weight regain occurs, hepatic steatosis tends to re-accumulate within 6 to 12 months, with ALT rising back toward baseline.